Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

NCT04082936 is registered in ClinicalTrials.gov with IGM Biosciences, Inc. as lead sponsor.

NCT NCT04082936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04082936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Lead sponsor
IGM Biosciences, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2019
Completion date
February 22, 2024
Enrollment
97 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, non-hodgkin lymphoma